Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Smith, Melody, García-Martínez, Elena, Pitter, Michael R., Fucikova, Jitka, Spisek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279325/
https://ncbi.nlm.nih.gov/pubmed/30524908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1526250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados